ruxolitinib + temozolomide

Ruxolitinib + temozolomide is a combination therapy being investigated primarily for the treatment of high-grade gliomas, including glioblastoma. Ruxolitinib is a JAK1/2 inhibitor that targets the JAK/STAT pathway, which has been associated with tumor progression and worse outcomes in glioblastoma patients. Temozolomide is a DNA-alkylating agent that works by damaging the DNA of tumor cells, preventing proper cell division. The combination has shown synergistic effects in preclinical studies, with ruxolitinib enhancing the cytotoxic and apoptotic effects of temozolomide in glioblastoma cells. Ruxolitinib's ability to cross the blood-brain barrier makes it particularly promising for brain cancer treatment. Clinical trials have shown that the combination appears to be safe and feasible, with preliminary survival data suggesting improved outcomes compared to historical benchmarks.